There are currently 18 clinical trials in Murfreesboro, Tennessee looking for participants to engage in research studies. Trials are conducted at various facilities, including International Clinical Research - Tennessee LLC, Tennessee Oncology, PLLC and Pfizer Investigational Site. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer
NCT05382286
Recruiting
The primary objective of this study is to compare the progression-free survival (PFS) between sacituzumab govitecan-hziy (SG) and pembrolizumab versus treatment of physician's choice (TPC) and pembrolizumab in participants with previously untreated, locally advanced inoperable or metastatic triple-negative breast cancer, whose tumors express programmed cell death ligand 1 (PD-L1).
Gender:
All
Ages:
18 years and above
Trial Updated:
12/06/2023
Locations: Tennessee Oncology, PLLC,1840 Medical Center Parkway, Murfreesboro, Tennessee
Conditions: Triple Negative Breast Cancer, PD-L1 Positive
Register for Updates
Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Patients With Previously Untreated Metastatic Triple-Negative Breast Cancer
NCT05382299
Recruiting
The primary objective of this study is to compare the progression-free survival (PFS) between sacituzumab govitecan-hziy (SG) versus treatment of physician's choice (TPC) in participants with previously untreated, locally advanced, inoperable or metastatic triple-negative breast cancer whose tumors do not express programmed cell death ligand 1 (PD-L1) or in participants previously treated with anti-programmed cell death (ligand or protein) 1 (Anti-PD-(L)1) Agents in the early setting whose tumor... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
12/05/2023
Locations: Tennessee Oncology, PLLC,1840 Medical Center Parkway, Murfreesboro, Tennessee
Conditions: Triple Negative Breast Cancer, PD-L1 Negative
Register for Updates
A Study to Evaluate Efficacy and Safety of Povorcitinib in Participants With Nonsegmental Vitiligo (STOP-V1)
NCT06113445
Recruiting
This study is being conducted to determine the efficacy and safety of povorcitinib in participants with nonsegmental vitiligo.
Gender:
All
Ages:
18 years and above
Trial Updated:
11/30/2023
Locations: International Clinical Research Tennessee Llc, Murfreesboro, Tennessee
Conditions: NonSegmental Vitiligo
Register for Updates
A Study to Evaluate the Efficacy and Safety of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa (HS)
NCT05620836
Recruiting
The purpose of this study is to evaluate the efficacy and safety of Povorcitinib (INCB054707) in participants with moderate to severe Hidradenitis Suppurativa (HS) over a 12-week placebo-controlled period, followed by a 42-week extension period.
Gender:
All
Ages:
18 years and above
Trial Updated:
11/29/2023
Locations: Investigative Site US232, Murfreesboro, Tennessee
Conditions: Hidradenitis Suppurativa (HS)
Register for Updates
A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Participants With Prurigo Nodularis (PN)
NCT05755438
Recruiting
The purpose of this study is to evaluate the safety and tolerability of Ruxolitinib cream in participants with Prurigo Nodularis (PN).
Gender:
All
Ages:
Between 18 years and 99 years
Trial Updated:
11/29/2023
Locations: International Clinical Research Tennessee Llc, Murfreesboro, Tennessee
Conditions: Prurigo
Register for Updates
Topical Ruxolitinib Evaluation in Chronic Hand Eczema
NCT05906628
Recruiting
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in adult participants with diagnosis of chronic hand eczema (CHE) and moderate to severe disease activity (Investigator's Global Assessement (IGA) of CHE score 3 or 4).
Gender:
All
Ages:
18 years and above
Trial Updated:
11/29/2023
Locations: International Clinical Research Tennessee Llc, Murfreesboro, Tennessee
Conditions: Hand Eczema
Register for Updates
Patient Retrospective Outcomes (PRO)
NCT01550575
Recruiting
This study will evaluate de-identified (anonymous) data in subject medical charts to review the clinical outcomes of various treatment approaches in the treatment of chronic pain.
Gender:
All
Ages:
18 years and above
Trial Updated:
11/14/2023
Locations: Comprehensive Pain & Neurology Center, Murfreesboro, Tennessee
Conditions: Chronic Pain
Register for Updates
Phase 2 Basket Trial of Nab-sirolimus in Patients With Malignant Solid Tumors With Pathogenic Alterations in TSC1/TSC2 Genes (PRECISION 1)
NCT05103358
Recruiting
A Phase 2 multi-center open-label basket trial of nab-sirolimus for adult and adolescent patients with malignant solid tumors harboring pathogenic inactivating alterations in TSC1 or TSC2 genes
Gender:
All
Ages:
12 years and above
Trial Updated:
11/13/2023
Locations: Sarah Cannon and HCA Research Institute, Murfreesboro, Tennessee
Conditions: Solid Tumor, Tumor, Tumor, Solid, Metastasis, Metastatic Cancer, Cancer, Cancer Metastatic, Tumors, Neoplasms, Neoplasm Metastasis, Advanced Solid Tumor, Advanced Cancer, Malignant Solid Tumor, Malignant Solid Neoplasm, Malignant Neoplasm, Malignant Tumor, TSC, TSC1, TSC2, Metastatic Solid Tumor, Metastatic Neoplasm
Register for Updates
A Study of Eltrekibart (LY3041658) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa
NCT06046729
Recruiting
This study aims to find the appropriately safe and effective dose and dosing frequency for eltrekibart in adults with moderate-to-severe hidradenitis suppurativa (HS) for further clinical development. The study will last approximately 62 weeks and may include up to 31 visits.
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
10/27/2023
Locations: International Clinical Research - Tennessee LLC, Murfreesboro, Tennessee
Conditions: Hidradenitis Suppurativa
Register for Updates
A Open-label Study to Assess the Long-term Safety of Difamilast Ointment 1% in Mild to Moderate Atopic Dermatitis
NCT05571943
Recruiting
This is a Phase 3, open-label study to evaluate the long-term safety of difamilast ointment 1% in subjects ≥2 years of age with mild to moderate AD. The study will also evaluate the long-term efficacy of difamilast ointment 1%, including durability of response.
Gender:
All
Ages:
2 years and above
Trial Updated:
10/19/2023
Locations: International Clinical Research - Tennessee, LLC, Murfreesboro, Tennessee
Conditions: Atopic Dermatitis
Register for Updates
A Study of Baricitinib (LY3009104) in Children From 6 Years to Less Than 18 Years of Age With Alopecia Areata
NCT05723198
Recruiting
The main purpose of this study is to determine the efficacy and safety of baricitinib for the treatment of severe or very severe alopecia areata (hair loss) in children from 6 years to less than 18 years of age. The study is divided into 4 periods, a 5-week Screening period, a 36-week Double-Blind Treatment Period, an approximately 2-year Long-term Extension Period, and a 4-week Post-treatment Follow-up period.
Gender:
All
Ages:
Between 6 years and 17 years
Trial Updated:
10/19/2023
Locations: International Clinical Research, Murfreesboro, Tennessee
Conditions: Areata Alopecia, Alopecia, Hypotrichosis, Hair Diseases, Skin Diseases, Pathological Conditions, Anatomical
Register for Updates
C-Brace Prospective Registry
NCT04640584
Recruiting
To gather prospective safety and effectiveness data for the C-Brace System following the standard of care.
Gender:
All
Ages:
All
Trial Updated:
10/16/2023
Locations: Restorative Health Services, Murfreesboro, Tennessee
Conditions: Pareses, Lower Extremity
Register for Updates